The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Treating psoriasis, a chronic inflammatory skin condition characterized by thick, scaly, red patches that can be itchy and painful, can be challenging if it appears on both the body and the scalp.

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

A higher intake of riboflavin was associated with a reduced risk of developing psoriasis, but no other single vitamin associations were observed.

Significant interaction seen for full psoriasis polygenic risk score with waist-to-hip ratio on psoriasis risk.

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.